Senseneuro

Sense Neuro operates at the intersection of neurotechnology, emergency medicine, medical devices, and digital diagnostics. Its NeuroHawk™ system is differentiated by the proposed use of an active RF headset to detect brain bleeds without conventional imaging infrastructure, targeting both field and hospital environments. That focus contrasts with established neurodiagnostic approaches such as CT and MRI, which generally require substantial equipment, controlled settings, and trained imaging personnel. The company also addresses a different use case from consumer brain-sensing platforms because its stated target customers are healthcare professionals managing stroke and severe traumatic brain injury. Sense Neuro’s potential market advantage depends on whether its technology can achieve clinically meaningful accuracy, rapid operation, workflow compatibility, and regulatory authorization. Its ISO 13485:2016-certified quality management system supports medical-device development and manufacturing processes, but certification alone does not establish product clearance or clinical adoption. The company’s Cincinnati base, emergency-care orientation, and relationship with St. Elizabeth Healthcare provide relevant healthcare context, while the limited commercial and competitive disclosures leave market share and differentiation beyond the technology concept uncertain.

Sense Neuro’s financing history shows a long development cycle followed by a potentially significant 2025 capital event. The company raised $1.3 million in Seed funding on Sep 9, 2019, followed by $250,000 from St. Elizabeth Healthcare on Mar 17, 2023. Leadership also shifted toward commercialization: Gary Kurdziel became Executive Vice President and Chief Commercial Officer on Oct 1, 2024 and Chief Executive Officer on Apr 1, 2025. The sequence suggests a move from technical and clinical development toward market execution. Product development remains centered on NeuroHawk™, an investigational active RF headset for non-invasive brain-bleed detection and real-time monitoring. Its trajectory is therefore best characterized as late-stage development and commercialization preparation rather than demonstrated commercial expansion.